Our Philosophy

Since its foundation in 1986, the philosophy of the PharmaMar Group has been to contribute to the improvement of society through the development of drugs to treat diseases for which there is no effective remedy, such as cancer.

Market Value

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom